Is high sensitive-troponin I a reliable biomarker for cardiac injury in methadone toxicity? A prospective cross-sectional study

Table 3 Distribution of cardiac outcomes at baseline and 30 days after study initiation across different categories hs-troponin

Endpoint	Hs-troponin positive (n = 12)		P*	Hs-troponin negative (n = 48)		P*	P^¶	P^ƪ
Endpoint	Baseline	After 30 days	P*	Baseline	After 30 days	P*	P^¶	P^ƪ
LVEF (%)	43.1 ± 15.4	43.7 ± 21.6	0.878	55	55.3 ± 1.2	0.083	< 0.001	< 0.001
Diastolic dysfunction (%)	3 (25)	2 (17)	0.317	4 (8)	4 (8)	0.346	0.108	0.389
Regional wall motion abnormalities (%)	5 (42)	3 (25)	0.483	0 (0)	2 (4)	0.511	< 0.001	0.020
LV size dilation (%)	5 (42)	2 (17)	0.375	0	0	1.00	< 0.001	0.004
Mitral regurgitation (%)	6 (50)	5 (42)	0.157	10 (63)	10 (21)	0.125	0.041	0.136
Tricuspid regurgitation (%)	6 (50)	4 (33)	0.572	7 (15)	7 (15)	0.553	0.008	0.133
Pulmonary arterial pressure (mmHg)	33.3 ± 9.3	32.9 ± 8.9	0.586	26.9 ± 5.02	28.9 ± 5.9	0.014	0.002	0.051

Hs-Troponin high sensitive troponin, LVEF left ventricular ejection fraction, LV left ventricle
* P value between baseline and after 30 days
¶ P value between hs-troponin positive and negative group at baseline
ƪ P value between hs-troponin positive and negative group after 30 days

ISSN: 2050-6511